Value of Abciximab in Patients With AMI Undergoing PCI After High Loading Dose of Clopidogrel Pretreatment - BRAVE-3


The goal of this trial was to assess if there was an incremental benefit from the use of abciximab, a glycoprotein (GP) IIb/IIIa inhibitor, in patients with ST-elevation myocardial infarction (STEMI) undergoing percutaneous coronary intervention (PCI), after pretreatment with 600 mg of clopidogrel.